A phase II single-arm study of the FGFR inhibitor pemigatinib in patients with metastatic colorectal cancer (mCRC) harboring FGF/FGFR alterations.

被引：0
|
作者：
Ciombor, Kristen Keon
Zemla, Tyler J.
Hubbard, Joleen M.
Jia, Jingquan
Gbolahan, Olumide B.
Sousa, Andrea
Wilson, Luke
Waechter, Blake
Ou, Fang-Shu
Nixon, Andrew B.
Bekaii-Saab, Tanios S.
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[2] Mayo Clin, Alliance Stat & Data Management Ctr, Rochester, MN USA
[3] Mayo Clin, Rochester, MN USA
[4] Duke Univ, Med Ctr, Durham, NC USA
[5] Emory Univ, Sch Med, Atlanta, GA USA
[6] Mayo Clin, Canc Ctr Scottsdale, Phoenix, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
139
引用
收藏
页码：139 / 139
页数：1
相关论文
共 50 条
  • [31] A phase II study of infigratinib in previously treated advanced/metastatic cholangiocarcinoma with FGFR gene fusions/alterations
    Javle, Milind M.
    Kelley, Robin Kate
    Springfeld, Christoph
    Abou-Alfa, Ghassan K.
    Macarulla, Teresa
    Tanasanvimon, Suebpong
    Goyal, Lipika
    Borbath, Ivan
    Bitzer, Michael
    Yong, Wei-Peng
    Philip, Philip Agop
    Alvarez-Gallego, Rafael
    Pande, Amit
    Shepherd, Stacie Peacock
    Fontaine, Jacki
    Roychowdhury, Sameek
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [32] Phase 2 study of futibatinib in patients with specific FGFR aberrations: Activity in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplification
    Satoh, T.
    Barthelemy, P.
    Nogova, L.
    Honda, K.
    Iwasa, S.
    Lee, K.
    Rha, S.
    Ajani, J.
    Hangai, N.
    Liu, S.
    Kremer, J.
    Mina, M.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S165 - S166
  • [33] A single-arm, phase II study of intrahepatic chemotherapy in patients with unresectable colorectal liver metastases
    Besel, Kate Elenna
    Ko, Yoo-Joung
    Karanicolas, Paul Jack
    Kim, Christina Yiyoung
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [34] Trastuzumab Combined with Irinotecan in Patients with HER2-Positive Metastatic Colorectal Cancer: A Phase II Single-Arm Study and Exploratory Biomarker Analysis
    Xu, Ting
    Wang, Xicheng
    Xin, Ying
    Wang, Zhenghang
    Gong, Jifang
    Zhang, Xiaotian
    Li, Yanyan
    Ji, Congcong
    Sun, Yu
    Zhao, Feilong
    Huang, Depei
    Bai, Yuezong
    Li, Jian
    Shen, Lin
    CANCER RESEARCH AND TREATMENT, 2023, 55 (02): : 626 - 635
  • [35] Efficacy and safety of fruquintinib dose-escalation strategy for elderly patients with refractory metastatic colorectal cancer: A single-arm, multicenter, phase II study
    Tan, Sirui
    Zhang, Shunyu
    Zhou, Nan
    Cai, Xiaohong
    Yi, Cheng
    Gou, Hongfeng
    CANCER MEDICINE, 2023, 12 (24): : 22038 - 22046
  • [36] Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial
    Lim, Sung Won
    Lee, Sujin
    Lee, Jeeyun
    Park, Se Hoon
    Park, Joon Oh
    Park, Young Suk
    Lim, Ho Yeong
    Kang, Won Ki
    Kim, Seung Tae
    JOURNAL OF CANCER, 2018, 9 (16): : 2910 - 2915
  • [37] First in human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced urothelial carcinoma (UC) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations.
    Garmezy, Benjamin
    Perez, Cesar Augusto
    Kato, Shumei
    Sharma, Manish
    Quah, Cheng Seok
    Tam, Betty
    Severson, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [38] First in human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations.
    Harding, James J.
    Perez, Cesar Augusto
    Kato, Shumei
    Sharma, Manish
    Garmezy, Benjamin
    Quah, Cheng Seok
    Tam, Betty
    Severson, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS637 - TPS637
  • [39] Interim analysis of a single-arm, phase II study of bevacizumab (BV) with modified OPTIMOX1 as first-line treatment of patients with metastatic colorectal cancer (mCRC): TCOG-GI0802
    Asano, M.
    Tanaka, S.
    Sato, A.
    Nakayama, N.
    Shimada, K.
    Konishi, K.
    Hibi, K.
    Sasaki, E.
    Kurihara, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [40] A phase II study of pembrolizumab, binimetinib, and bevacizumab in patients with microsatellitestable, refractory, metastatic colorectal cancer (mCRC)
    Friedrich, Tyler
    Blatchford, Patrick Jud
    Lentz, Robert William
    Davis, S. Lindsey
    Kim, Sunnie S.
    Leal, Alexis Diane
    Van De Voorde, Zoe
    Lee, Matthew R.
    Waring, Meredith
    Cull, Tiffany
    Martin, Anne
    Eckhardt, S. Gail
    Messersmith, Wells A.
    Lieu, Christopher Hanyoung
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
12345